BIOENGINEER

Programmable RNA demethylation re-sensitizes bladder cancer to cisplatin

Cisplatin-based chemotherapy remains a cornerstone of treatment for advanced bladder cancer, yet resistance to this platinum ...
blackdoctor

Bladder Leaks After a Hysterectomy? Here’s What Can Help

A hysterectomy can be used to treat multiple conditions such as uterine fibroids, endometriosis, or cancer that affects the ...
oncodaily

Sia Daneshmand: Combining Treatments to Improve Durable Responses in Non-Muscle-Invasive Bladder Cancer

Combining Treatments to Improve Durable Responses in Non-Muscle-Invasive Bladder Cancer / bladder-preserving therapies, ...

Dear Doctor: What's really waking me up at night, my bladder, my prostate or my sleep apnea?

Finally, finasteride and tamsulosin are common drugs to treat the symptoms of an enlarged prostate. They typically improve ...

Dear Doctor: Is my bladder waking me up, or is my sleep apnea still calling the shots?

A 74-year-old man with central sleep apnea and an enlarged prostate asks whether his nightly urination stems from his ...
The Eastern Herald

FDA Clears Anktiva for Papillary Bladder Cancer on Extrapolated Data

The FDA extended Anktiva to high-grade papillary-only bladder cancer that no longer responds to BCG. Its reasoning rests on a ...
Senior Book on MSN

The hidden reasons seniors may lose bladder control

Bladder or bowel control problems can quietly affect a senior's confidence and independence. A small leak while coughing or ...
Medindia

FDA Expands Anktiva Approval for Bladder Cancer Patients

FDA expands Anktiva approval for BCG-unresponsive bladder cancer. Learn about the 62% trial response, eligible patients, ...
healthandme

FDA Approves New Treatment Option For Bladder Cancer Unresponsive To Standard Immunotherapy

The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...
Drug Target Review

Bacterial microrobot platform achieves 82 percent tumour inhibition in bladder cancer

A hybrid microrobotic platform combining living bacteria, nanoparticles and targeted chemotherapy has achieved 82.4 percent ...

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® ...